A Clinical Measure Sensitive to Treatment Effects
The Schizophrenia Cognition Rating Scale (SCoRS) is a 20 item interview-based clinical assessment that evaluates cognitive deficits and the degree to which these deficits impair patients’ day-to-day functioning. It was originally developed in 2001 at the Duke University Medical Center by Dr. Richard Keefe and is licensed through NeuroCog Trials. The SCoRS is used in clinical trials, academic research, and in clinical settings.
The SCoRS contains questions about the patient’s ability to manage cognitively demanding, functionally relevant, everyday tasks such as conversations, watching television, and using electronic devices. The items were developed to assess the following cognitive domains:
- Working Memory
- Language Production
- Problem Solving
- Motor Skills
- Social Cognition
The SCoRS is currently being used as a co-primary endpoint in several international phase 2 and phase 3 trials assessing cognitive treatment change in schizophrenia, and has been permitted by the FDA for pivotal registration trials. As an interview-based assessment of cognition, the SCoRS meets the criteria established by the FDA-NIMH-MATRICS panel for co-primary outcome measures for cognitive enhancement trials in schizophrenia.